Business
Opthea Announces Decision to Discontinue Wet AMD Trials
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage b
About this update from Opthea Limited
[{"type":"image","alt":"Opthea Limited","displaySize":"","headline":null,"caption":"Opthea Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/c07427df91ee1cd5a8b901317d4291e5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ULDvHcvRToYWZzZCS40V5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/c07427df91ee1cd5a8b901317d4291e5","width":182,"height":44}},"lazy":false},{"type":"text","content":"ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52","length":126,"tagName":"p"},{"type":"text","content":"Opthea and DFA Investors agreed to terminate both COAST and ShORe trials","length":72,"tagName":"p"},{"type":"text","content":"Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern ","length":145,"tagName":"p"},{"type":"text","content":"MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on its Phase 3 clinical program, including the termination of COAST (Combination of OPT-302 with Aflibercept Study) and accelerated topline results from its second Phase 3 trial ShORe (Study of OPT-302 in combination with Ranibizumab) in patients with wet AMD.","length":608,"tagName":"p"},{"type":"text","content":"ShORe Topline Results","length":21,"tagName":"p"},{"type":"text","content":"Following the negative results of the COAST Phase 3 trial announced on 24 March 2025, Opthea determined that the most appropriate course of action for wet AMD patients, shareholders, and other stakeholders was to accelerate the ShORe trial topline data readout, including in consultation with its Development Funding Agreement investors (“DFA Investors”).","length":355,"tagName":"p"},{"type":"text","content":"The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four...